Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06690177 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers
A Phase 2 study, sponsored by MediWound.
- Not yet
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT06690177 is a Phase 2 study that has not yet begun recruiting, run by MediWound. The registered enrollment target is 45 participants.
The verdict
NCT06690177, a Phase 2 study, has not yet begun recruiting, sponsored by MediWound.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The main objective of this study is: To assess the safety of EscharEx (EX-03 5% formulation) compared to placebo control and compared to Collagenase (NSSOC) in patients with VLU.
Interventions
- DRUG EscharEx (EX-03)
- DRUG Placebo (Gel vehicle)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06690177
The ClinicalTrials.gov registry entry for NCT06690177 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediWound, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EscharEx (EX-03) is the first listed.
NCT06690177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06690177 about?
NCT06690177 is a clinical study titled "Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers". The main objective of this study is: To assess the safety of EscharEx (EX-03 5% formulation) compared to placebo control and compared to Collagenase (NSSOC) in patients with VLU.
What is the current status of trial NCT06690177?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-04-30. Estimated completion is 2028-09-30.
What interventions are being tested in trial NCT06690177?
The interventions under investigation include: EscharEx (EX-03) (DRUG), Placebo (Gel vehicle) (DRUG).
Who is sponsoring clinical trial NCT06690177?
This trial is sponsored by MediWound, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.